WANG Rubing
Research experience
10/2018-present: Associate professor, Institute of Materia Medica, CAMS & PUMC
09/2015-09/2018: Assistant professor, Institute of Materia Medica, CAMS & PUMC
Education background
08/2013-07/2015: Medicinal chemistry, Postdoctoral Fellow, California State University
09/2009-06/2013: Ph.D., Medicinal chemistry, School of pharmacy, Shanghai Jiao Tong University
09/2006-06/2009: M.Sc., Chemistry, School of pharmacy, China Pharmaceutical University
Research interests
1. Synthetic Medicinal Chemistry
2. Synthetic Methodology
3. New Drug Research and Development
Dr. Wang has been working on medicinal chemistry research since 2006 and his research involves natural product discovery, structural modification, total synthesis, and new synthetic methodology research. His research results and findings have been published in almost 50 publications, including around 20 publications as first author or corresponding author in core journals, such as, Chemical Science, Journal of Medicinal Chemistry, Organic Letter, European Journal of Medicinal Chemistry, etc. He has been granted 7 China patents (applied for 12 ones), and applied for a PCT patent, which has been granted in the US and the EU.
1. Library construction of stereochemically diverse isomers of spirooliganin: their total synthesis and antiviral activity. Chem. Sci. 2021, 12: 7003-7011.
2. Illihenin A, an antiviral sesquiterpenoid with a cage-like tricyclo[6.2.2.01,5]dodecane skeleton from Illicium henryi. J. Org. Chem. 2021, 86: 2017-2022.
3. A role for isatin azomethine imines as a dipolarophile in cycloaddition reactions. Org. Lett. 2020, 22: 7358-7362.
4. Burchellin and its stereoisomers: total synthesis, structural elucidation and antiviral activity. Org. Biomol. Chem. 2020,18: 9081-9087.
5. DABCO-mediated [3+3] cycloaddition of azomethine imines with in situ generated nitrile oxides from hydroximoyl chlorides. Chem. Commun. 2019, 55: 10587-10591
6. New glycosides from the twigs and leaves of Rhododendron latoucheae. J Asian Nat Prod Res. 2019, 21: 299-307.
7. Two azafluoranthene alkaloids and a phytoecdysone from the stems of Cyclea barbata. J. Asian Nat. Prod. Res., 2019, 21: 217-226.
8. A novel and practical synthesis of CAT3: a phenanthroindolizidine alkaloid with potential in treating glioblastoma. RSC Adv. 2018, 8: 29301-29308.
9. New C-2 diastereomers of flavanone glycosides conjugated with 3-hydroxy-3- methylglutaric acid from the pericarp of Citrus grandis (L.) Osbeck. Bioorg. Chem. 2018, 80: 519-524.
10. Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models. Eur. J. Med. Chem. 2017, 133: 208-226.
11. Synthesis and evaluation of 1,7- diheteroarylhepta-1,4,6-trien-2-ones as promising anticancer agents. Eur. J. Med. Chem. 2016, 110: 164-180.
12. Structure-activity relationship and pharmacokinetic studies of 1,5-diheteroarylpenta- 1,4-dien-3-ones: A class of curcumin-based anticancer agents. J. Med. Chem. 2015, 58: 4713-4726.
13. Design, synthesis and biological evaluation of shikonin and alkannin derivatives as potential antitumor agents via a prodrug approach. ChemMedChem 2014, 9: 2798-2808.
14. Synthesis and evaluation of alkannin and shikonin oxime derivatives as potent antitumor agent. Bioorg. Med. Chem. Lett. 2014, 24: 4304-4307.
